What are the indications, dosing regimen, contraindications, and monitoring recommendations for Jardiance (empagliflozin) in adults with type 2 diabetes?

Jardiance (Empagliflozin) for Type 2 Diabetes

Start empagliflozin at 10 mg once daily in the morning, with or without food, for adults with type 2 diabetes who need cardiovascular or renal protection, regardless of baseline glycemic control. 1, 2

Indications

Empagliflozin has three FDA-approved indications 2:

1. Reduce cardiovascular death and heart failure hospitalization in adults with heart failure (with or without diabetes)
2. Reduce cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
3. Improve glycemic control as adjunct to diet and exercise in adults with type 2 diabetes

The 2020 ACC Expert Consensus specifically identifies empagliflozin for reducing CV death risk in adults with type 2 diabetes and established CV disease 1. More recent evidence from 2022 supports its use for CKD progression prevention in patients with eGFR ≥20 mL/min/1.73 m² 3.

Dosing Regimen

Initial dose: 10 mg once daily in the morning 1, 2

Dose escalation: May increase to 25 mg once daily if additional glycemic control is needed and the patient tolerates the 10 mg dose 2. However, there is no graded dose-response for cardiovascular or renal benefits—the 10 mg dose tested in outcomes trials provides full CV/renal protection 1. The higher dose only offers incremental glucose-lowering benefit.

Administration: Take with or without food 2

Dose Modifications Based on Renal Function

The dosing guidance has evolved significantly and varies by indication:

For glycemic control 1, 4:

• eGFR ≥45 mL/min/1.73 m²: No adjustment required
• eGFR <45 mL/min/1.73 m²: Not recommended for initiation for glucose lowering (reduced efficacy)

For cardiovascular/renal protection 3, 4:

• Can be initiated down to eGFR ≥20 mL/min/1.73 m² 3
• Once started, continue until dialysis even if eGFR declines below initiation threshold 4
• The 2022 ADA/KDIGO consensus supports use with eGFR ≥20 mL/min/1.73 m² for kidney and CV benefits 4

Critical distinction: The eGFR <45 mL/min/1.73 m² restriction applies only to glucose-lowering efficacy, not to cardiovascular or renal protection. The CV and renal benefits persist down to eGFR of 30 mL/min/1.73 m² and potentially lower 5.

Contraindications

Absolute contraindications 1, 2:

• History of serious hypersensitivity reaction to empagliflozin
• Patients on dialysis
• End-stage renal disease (ESRD)

Not recommended 2:

• Type 1 diabetes (increased diabetic ketoacidosis risk)
• Severe renal impairment for glycemic control purposes

Cautions and Important Safety Considerations

Pre-Treatment Assessment

Before initiating empagliflozin 1, 2:

• Assess and correct volume depletion, especially in patients with:
  • Impaired renal function
  • Elderly patients
  • Patients on loop diuretics
  • Low systolic blood pressure

Key Safety Warnings

1. Euglycemic Diabetic Ketoacidosis 1, 2

• Can occur even with normal blood glucose levels
• Discontinue at least 3 days before planned surgery to prevent postoperative ketoacidosis 1
• Assess patients presenting with metabolic acidosis symptoms regardless of glucose level
• Higher risk in situations with prolonged fasting, carbohydrate restriction, or insulin dose reductions

2. Volume Depletion 1, 2

• Monitor for signs/symptoms of intravascular volume contraction
• Consider stopping or reducing diuretic dose when initiating empagliflozin 1
• Higher risk in elderly, those with renal impairment, or on diuretics

3. Genital Mycotic Infections 1, 2

• More common in women than men
• Monitor and treat appropriately
• Daily hygienic measures may reduce risk

4. Urinary Tract Infections and Urosepsis 1, 2

• Evaluate and treat promptly if signs/symptoms develop
• Rare cases of serious urosepsis and pyelonephritis reported

5. Necrotizing Fasciitis of the Perineum (Fournier's Gangrene) 2

• Rare but life-threatening
• Assess patients with pain, tenderness, erythema, or swelling in genital/perineal area with fever
• Institute prompt treatment if suspected

Concomitant Medication Adjustments

When starting empagliflozin 1:

• If HbA1c well-controlled at baseline or history of frequent hypoglycemia:
  • Wean or stop sulfonylurea or glinide
  • Consider reducing total daily insulin dose by approximately 20%

This prevents hypoglycemia since empagliflozin adds glucose-lowering effect without intrinsic hypoglycemia risk.

Monitoring Recommendations

Adverse effects to monitor 1:

• Genital fungal infections
• Urinary tract infections
• Signs of euglycemic diabetic ketoacidosis
• Volume depletion symptoms (dizziness, orthostatic hypotension)
• Renal function (eGFR)

Laboratory monitoring:

• Baseline eGFR before initiation
• Periodic eGFR monitoring, especially in patients with declining renal function
• Ketone testing (urine or blood) if metabolic acidosis suspected

Common Pitfalls to Avoid

1. Don't withhold empagliflozin solely based on eGFR 30-44 mL/min/1.73 m² if the indication is cardiovascular or renal protection rather than glycemic control. The older labeling focused on glucose-lowering efficacy; newer evidence supports CV/renal benefits at lower eGFR 3, 4.

2. Don't forget to reduce insulin/sulfonylurea doses when adding empagliflozin to avoid hypoglycemia 1.

3. Don't continue empagliflozin perioperatively—stop at least 3 days before surgery to prevent ketoacidosis 1.

4. Don't ignore volume status—assess and correct dehydration before starting, especially in vulnerable populations 2.

5. Don't assume normal glucose excludes ketoacidosis—empagliflozin can cause euglycemic DKA 2.

Special Populations

Pregnancy 2: Advise females of potential fetal risk, especially during second and third trimesters

Lactation 2: Not recommended when breastfeeding

Geriatric patients 2: Higher incidence of volume depletion and renal function-related adverse reactions; use caution and monitor closely

Renal impairment 2: Higher incidence of adverse reactions related to reduced renal function; follow eGFR-based dosing guidance above